SCHEMBL24499263

SCHEMBL24499263

CC(C)c1ccccc1Sc1ccccc1CO

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APOBEC3G Q9HC16 1/20 0.52
SLC6A4 P31645 7/20 0.48
GABRA1 P14867 2/20 0.46
GABRG2 P18507 1/20 0.46
GABRB3 P28472 1/20 0.46
SLC6A2 P23975 4/20 0.43
P4HB P07237 1/20 0.42
GABRB2 P47870 1/20 0.39
SLC6A3 Q01959 1/20 0.38
IFNAR1 P17181 1/20 0.38
KMT2A Q03164 1/20 0.38
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
NPY1R P25929 1/20 0.37
MAPK1 P28482 1/20 0.37
NPY2R P49146 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
GFER P55789 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5147854 0.86 APOBEC3G (0.48) APOBEC3GSLC6A4SLC6A2P4HBSLC6A3
SCHEMBL26505559 0.84 P4HB (0.40) SLC6A4GABRA1SLC6A2P4HBGABRB2
SCHEMBL4442278 0.82 APOBEC3G (0.73) APOBEC3GSLC6A4SLC6A2P4HBSLC6A3
SCHEMBL30389926 0.82 GABRA1 (0.48) GABRA1GABRG2GABRB3SLC6A2GABRB2
SCHEMBL4808650 0.82 GABRA1 (0.48) GABRA1GABRG2GABRB3SLC6A2GABRB2
SCHEMBL357956 0.78 GABRA1 (0.58) APOBEC3GSLC6A4GABRA1GABRG2GABRB3
SCHEMBL18795670 0.78 SLC6A4 (0.48) APOBEC3GSLC6A4SLC6A2P4HBSLC6A3
SCHEMBL30711874 0.78 SLC6A4 (0.48) APOBEC3GSLC6A4SLC6A2P4HBSLC6A3
SCHEMBL73812 0.77 APOBEC3G (0.59) APOBEC3GSLC6A4GABRA1SLC6A2GABRB2
SCHEMBL18795171 0.77 SLC6A4 (0.47) APOBEC3GSLC6A4SLC6A2P4HBSLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230139111-A1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2023-05-04 US disclosed
US-20220177462-A1 SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2022-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230139111-A1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF RIPK1, RIPK4, RIPK3 APOBEC3G 4655/4885SLC6A4 1329/4885GABRA1 2875/4885
US-20220177462-A1 SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF RIPK1, RIPK4, RIPK3 APOBEC3G 4592/4885SLC6A4 3638/4885GABRA1 2703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.